Concurrent dual staining for CD11b and hTERT was not possible because ... the intranuclear hTERT antigen interfered with the CD11b antibody's action. The assay was applied to primary blood cells ...

A neutralizing antibody therapy targeting the conserved stalk region of the H5N1 hemagglutinin protein reduced disease severity and prevented death in monkeys exposed to avian flu.

Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer The advent of next-generation antibody-drug conjugates (ADCs), particularly ...

Antidrug antibody (ADA) titers and neutralizing antibody-positive status were determined on cycle 1 day 1 (predose) and day 8, then on day 1 of every even cycle, and at end-of-treatment and follow-up ...

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody ...

Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established benefit in RA both with regards to clinical efficacy and ...

Alchemab, which is based in the U.K., seeks to develop antibody therapies for ALS and other conditions. Their approach involves analyzing antibodies that occur naturally in people who are resilient to ...

Sanofi and IGM first partnered up in March 2022, when the pharma fronted $150 million to co-develop six IgM antibody agonists—three against cancer indications and three for immunology or inflammation ...

CS2009 is a promising trispecific antibody targeting PD-1, VEGFA, and CTLA-4, which demonstrates broad clinical application prospects for solid tumors with the great potential to become the ...